Teosyal PureSense Redensity 2 2x1ml
Important Notice
Medical device regulated by the European Medical Device Regulation (MDR), intended exclusively for authorized healthcare professionals. By purchasing, the customer declares to be authorized for their professional activity; false information may entail legal responsibilities.
Teosyal® PureSense Redensity 2 is Teoxane's periorbital reference: 15 mg/ml of hyaluronic acid with a degree of cross-linking below 10 %, combined with the same dermo-restructuring complex of 8 amino acids, 3 antioxidants, vitamin B6, zinc and copper as Redensity 1. It is formulated specifically for the tear trough and the eye contour, where the skin is thin and water retention must be contained.
- HA 15 mg/ml
- Cross-linking < 10 % (NMR)
- Lidocaine 0.3 % (3 mg/ml)
- Contents 2 syringes × 1 ml
- Needles 4 × 30G ½"
- Duration ≥ 12 months
Composition and technology
- Cross-linked hyaluronic acid: 15 mg/ml.
- Degree of cross-linking: < 10 %, measured by nuclear magnetic resonance.
- Lidocaine hydrochloride: 0.3 % by mass (3 mg/ml).
- Residual BDDE: < 1 ppm.
- Dermo-restructuring complex (supplemented phosphate buffer, pH 7.3): the buffer is not inert, it incorporates the following active components:
- 3 antioxidants: α-lipoic acid, glutathione and N-acetyl-L-cysteine.
- 8 amino acids: L-arginine, L-isoleucine, L-leucine, L-lysine monohydrate, glycine, L-valine, L-threonine and L-proline — precursors for collagen and elastin synthesis.
- 1 vitamin: pyridoxine (vitamin B6) in the form of the hydrochloride.
- 2 minerals: zinc acetate dihydrate and copper sulphate pentahydrate, enzyme cofactors.
- Sodium chloride.
- Difference from Redensity 1: the same HA concentration and the same associated complex, but Redensity 2 is indeed cross-linked. This allows it to create a volume that corrects the trough, whereas Redensity 1 only redensifies. The estimated duration goes from at least 3 months to at least 12.
Position within the Teosyal PureSense range
| Redensity 1 | Non-cross-linked HA 15 mg/ml + dermo-restructuring complex · 1 ml · 30G ½" — skin quality and hydration · ≥ 3 months |
|---|---|
| Redensity 2 (this product) | HA 15 mg/ml (cross-linking < 10 %) + dermo-restructuring complex · 1 ml · 30G ½" — periorbital region and tear trough · ≥ 12 months |
| Global Action | HA 25 mg/ml · 1 ml — wrinkles and skin depressions, lips · 12–18 months |
| Deep Lines | HA 25 mg/ml · 1 ml — marked wrinkles and depressions · 12–18 months |
| Kiss | HA 25 mg/ml (cross-linking < 10 %) · 1 ml · 27G ½" — lips and perioral region · 12–18 months |
| Ultra Deep | HA 25 mg/ml (cross-linking < 10 %) · 1.2 ml · 25G 1" — facial volume and contour · 15–18 months |
| Ultimate | HA 22 mg/ml · 1 ml — facial contour · 15–18 months |
The cross-linked PureSense range declares a degree of cross-linking below 10 % (NMR), compared with the < 5 % of the RHA range. It is a firmer gel with a greater capacity for projection at an equal concentration; the RHA range instead prioritises adaptation to movement in areas of high facial animation. Redensity 1 falls outside this logic: it is not cross-linked and provides no volume.
Indications and treatment areas
Correction of superficial fine lines and wrinkles and of depressions in:
- Periorbital region: dark circles — tear trough and palpebromalar groove —, eyebrows, lateral canthus and crow's feet
- Midface: nasojugal groove
Contraindication specific to this reference: it must not be used in the presence of eyelid bags or laxity of the lower eyelid.
Technique and treatment protocol
- Injection plane: dermis, subcutaneous or supraperiosteal plane.
- Needles included: 30G ½", two per syringe (4 per pack).
- Maximum volume: 6 ml per session; in the tear trough, a maximum of 0.5 ml per side.
- Estimated duration: at least 12 months.
- Do not inject into the epidermis. Exercise the utmost caution in the periorbital area because of its vascular risk. Do not combine in the same session with peeling, laser or ultrasound.
Technical data
| Manufacturer | Teoxane SA (Laboratoires Teoxane), Geneva, Switzerland |
|---|---|
| Active substance | Cross-linked hyaluronic acid 15 mg/ml |
| Degree of cross-linking | < 10 % (NMR) |
| Anaesthetic | Lidocaine HCl 0.3 % by mass |
| Cross-linker | BDDE, residual < 1 ppm |
| Associated complex | 8 amino acids, 3 antioxidants, vitamin B6, zinc and copper |
| pH | 7.3 (supplemented phosphate buffer) |
| Presentation | 2 pre-filled syringes of 1 ml |
| Needles | 4 × 30G ½" (2 per syringe) |
| Treatment plane | Dermis, subcutaneous or supraperiosteal |
| Estimated duration | At least 12 months |
| Classification | CE-marked medical device |
| Use | Qualified healthcare professionals only |
Storage and pack contents
- Storage: between 2 °C and 25 °C, protected from direct sunlight.
- Do not use after the expiry date stated on the pack.
- Sterile single-use product. Do not reuse or re-sterilise the syringe or the needles.
- The pack contains: 2 pre-filled syringes of 1 ml, 4 sterile 30G ½" needles, and two traceability labels per syringe — one to be given to the patient and one for the medical record.
Contraindications and warnings
Contraindications: skin disorders, inflammation or infection in or near the treatment area; allergy to hyaluronic acid and a history of severe allergy or anaphylactic shock; allergy to lidocaine or to amide-type local anaesthetics; recent peel, laser or ultrasound treatment; autoimmune diseases; heart disease or treatment with beta-blockers; hepatocellular insufficiency or treatment for liver disease; epilepsy; porphyria; pregnancy, breastfeeding and patients under 18 years of age.
Additional contraindication for Redensity 2: eyelid bags or laxity of the lower eyelid.
Vascular warning: intravascular injection may cause vascular occlusion, ischaemia and necrosis of the treated area. In the most serious cases it may lead to visual disturbances or blindness and to cerebral ischaemia or haemorrhage. Never inject intravascularly.
Before injection: do not treat if a dental procedure has been performed in the previous 15 days; avoid aspirin, anti-inflammatory drugs, anticoagulants and vitamin E during the preceding week; avoid alcohol and intense sun exposure on the previous day and on the day itself; remove make-up completely.
After injection: during the first 12 hours, do not apply make-up or undertake intense exertion; during the following week, avoid alcohol, prolonged sun or UV exposure, temperatures below 0 °C, sauna and hammam; for 15 days, do not undergo dental procedures or other aesthetic treatments.
Always consult the instructions for use included in the pack before treatment.
Medical device intended exclusively for qualified healthcare professionals. Technical information based on the official documentation of Teoxane SA (instructions for use TEOSYAL® PureSense REDENSITY 2, ref. 230588-00, and patient product information). This information sheet does not replace the instructions for use supplied with the product.